Anti-HIV effects of chloroquine: Mechanisms of inhibition and spectrum of activity

AIDS

Volumn 15, Issue 17, 2001, Pages 2221-2229

  Savarino, Andrea ^a   Gennero, Luisa ^a   Hou, Chu Chen ^a   Serrano, David ^a   Malavasi, Fabio ^a   Boelaert, Johan R ^a   Sperber, Kirk ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Gp120; HIV 1 infectivity; HIV 1 subtypes; HIV 2; Low cost medications; Third World

Indexed keywords

CHLOROQUINE; EPITOPE; GLYCOPROTEIN GP 120;

ANTIGEN ANTIBODY REACTION; ANTIVIRAL ACTIVITY; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPRECIPITATION; IN VITRO STUDY; MONONUCLEAR CELL; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; VIRUS ENVELOPE; VIRUS INFECTION; VIRUS INHIBITION; VIRUS ISOLATION;

ANTI-HIV AGENTS; CELL LINE; CHLOROQUINE; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP120; HIV-1; HIV-2; HUMANS; SPECIES SPECIFICITY; VIRUS REPLICATION;

EID: 0035941397     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200111230-00002     Document Type: Article

References (33)

1. Inhibition of human immunodeficiency virus infectivity by chloroquine
2. Experimental results on chloroquine and AIDS opportunists
3. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with HIV-1
4. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1
5. Inhibitors of human immunodeficiency virus integrase
6. Inhibition of HIV-1 Tat transactivation by quinacrine and chloroquine
7. The anti-HIV-1 activity of chloroquine
8. Chloroquine exerts an additive in vitro anti-HIV type 1 effect when associated with didanosine and hydroxyurea
9. Effects of the human CD38 glycoprotein on the early stages of the HIV-1 replication cycle
10. Basic approaches to anti-retroviral treatment
11. Sequence specificity of the human immunodeficiency virus type 2 (HIV-2) long terminal repeat u3 region in vivo allows subtyping of the principal HIV-2 viral subtypes A and B
12. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery
13. Investigation of the potential role of membrane CD38 in protection against cell death induced by HIV-1
14. Detection of simian immunodeficiency virus and human immunodeficiency virus type 2 capsid antigens by a monoclonal antibody-based antigen capture assay
15. Modulation of surface transferrin receptors in lymphoid cells de novo infected with human immunodeficiency virus type 1
16. Chronically HIV-1 infected monocytic cells induce apoptosis in co-cultured T cells
17. Surface expression of CD4 does not predict susceptibility to infection with HIV-1 in human monocyte hybridomas
18. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immunization
19. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
20. Neutralization of HIV-1 by F105, a human monoclonal antibody to the CD4 binding site of gp120
21. An IgG human monoclonal antibody that reacts with HIV-1 gp120, inhibits virus binding to cells, and neutralizes infection
22. Importance of hypervariable regions of HIV-1 gp120 in generation of virus neutralizing antibodies
23. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements
24. The neutralizing antibody response to HIV-1: Viral evasion and escape from humoral immunity
25. Chloroquine and ammonium chloride prevent terminal glycosylation of immunoglobulins in plasma cells without affecting secretion
26. Thiamine disulfide as a potent inhibitor of human immunodeficiency virus (type-1) production
27. Effects of chloroquine on iron metabolism in a lymphocytic cell line
28. Iron metabolism and HIV infection: Reciprocal interactions with potentially harmful consequences?
29. Inhibition of HIV-1 replication by hydroxychloroquine: Mechanism of action and comparison with zidovudine
30. Processing of the structural proteins of human immunodeficiency virus type 1 in the presence of monensin and cerulenin
31. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells
32. The potential place of chloroquine in the treatment of HIV-1-infected patients
33. Chloroquine exerts an additive in vitro anti-HIV-1 effect, when combined to zidovudine and hydroxyurea